Watch the webinar

Enter your details below to access the audio and video recording of this event, and to receive updates about future virtual events.

If you’re already subscribed to IN-PART, please enter your details and you’ll be taken to the recordings.

In the second event of our Virtual Series, we hosted an ‘academic partnering opportunity’ event with the National Institutes of Health and National Cancer Institute to find out more about their microbiome research programmes, expertise, and collaboration opportunities.

If you would like to speak with our guests from the NIH/NCI please fill in the introduction request form, or contact Joe at IN-PART (joseph.ferner@in-part.co.uk) who will connect you. 


What’s covered in this event?

  • 00:00 – Introduction to the event from IN-PART
  • 03:57 – Introduction to the NIH
  • 08:37 – Dr Tim F. Greten: Targetting the gut microbiome to treat liver cancer
  • 16:51 – Dr Rashmi Sinha: Moving microbiome research into population studies
  • 27:53 – Additional Opportunities at the NIH
  • 28:46 – Partnering with the NIH
  • 32:20 – Live Q&A 
  • 38:52 – Closing remarks

Format: Presentation followed by live Q&A (~45 minutes)


Speakers from the NIH: 

Dr Tim Greten, Co-director, Liver Cancer Program at the Center for Cancer Research, National Cancer Institute

Dr. Greten is a physician-scientist who uses his medical expertise in Gastroenterology, Hepatology and Medical Oncology along with his research expertise in tumor immunology to develop novel treatments for patients with cancer. He heads a research team to study the tumor microenvironment in the liver in the context of Hepatocellular Carcinoma, Cholangiocarcinoma, and liver metastasis and studies how exogenous factors such as diet and the gut microbiome may affect immune responses in the liver. 


Dr. Rashmi Sinha, Senior Investigator, Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute

Dr. Sinha received a B.S. with honors and M.SC. in biochemistry from the University of Stirling in Scotland, and a Ph.D. in nutritional sciences from the University of Maryland. She began work at the NCI in the Laboratory of Cellular Carcinogenesis and Tumor Promotion in 1987. Dr. Sinha was promoted to senior investigator in 2001 and co-principal investigator of the NIH-AARP Diet and Health Study. She served for many years as Deputy Chief of the Nutritional Epidemiology Branch.


Dr. Emily Krach, Invention Development and Marketing Fellow, NCI Technology Transfer Center

Dr. Emily Krach is a post-doctoral fellow in the National Cancer Institute (NCI) Technology Transfer Center. As part of the Technology Analysis and Marketing Unit, she facilitates the commercial development of NCI innovations by initiating collaborations with and licensing to industry partners. Emily received her PhD in Genetics from the University of Georgia in 2021.


Dr. Michael Salgaller, SSupervisory Technology Analysis and Marketing Specialist, NCI Technology Transfer Center

Dr. Michael Salgaller leads the Technology Analysis and Marketing Unit (TAMU) within the National Cancer Institute’s (NCI’s) Technology Transfer Center, where he leverages over 20 years of business, scientific, and investment experience in various life science sectors to support technology development and commercialization. The TAMU serves in a business development role to foster licensing and collaborative activity between buy-side stakeholders and the NCI (as well as NIH in general). Dr. Salgaller received his PhD in Pathology from The Ohio State University.


More Information:

Our bodies are home to an estimated 39 trillion microbial cells. These cells make up the human microbiome, communities of microbes, including bacteria and fungi that have greater complexity than the human genome itself. The microbiome can be found in multiple sites across the human body, for example, the gut, skin, and oral and nasal cavities which all host a distinct community of microbes. 

As the key interface between the body and the environment, the human microbiome has extensive functions to protect us against pathogens, develop immunity and aid in digestion and metabolism.

For Event 2 of our Virtual Series, we’ve launched our first-ever academic partnering opportunity, which presents both industry and academia with a chance to learn about the collaboration opportunities at NIH around microbiome research. 

An overview of the topics covered include:

  • An overview of microbiome research programmes, expertise, and collaboration opportunities at the NIH
  • NIH’s objectives, mission, and offering as a trusted and disruptive partner
  • A live audience Q&A 

The NIH mission to facilitate economic development is lesser known than their academic research and funding initiatives. Many companies (large and small) are unaware of the partnering opportunities and advantages to working with NIH for technology development.  Being a government agency, they have a different business model than other research institutions that, in many ways, translates to competitive business and financial terms for a company.

Run in partnership with:

ASTP are Europe’s premier association of knowledge transfer professionals whose work aims to improve the quality of impact that public research has on the economy and society. Learn more.

PraxisAuril are a world-leading professional association for knowledge exchange practitioners, whose network includes 5000+ KE professionals. Learn more.

What is IN-PART?

IN-PART develops digital solutions, curated by in-house STEM experts, that simplify the initial connection between decision-makers in academia and industry. Our goal is to help drive impact from research by matching innovation and expertise on a level playing field globally.

Connect, a digital partnering platform for university-industry collaboration.

An online matchmaking platform used by 250+ universities and research institutes to connect with industry teams in 6,000+ companies to commercialise academic innovations and expertise that are available and seeking collaboration. 

Discover, a bespoke scouting service for open innovation.

A bespoke scouting platform used by innovation-driven companies to profile the global landscape of academia across an active network of 2,400+ institutes, either through ‘Industry Calls for Opportunities’ or ‘Request for Proposal’ campaigns that find and confirm potential solutions to specific R&D challenges or requirements. 

Working in a company?

Gain a competitive advantage by identifying cutting-edge innovation and expertise from universities and institutes worldwide.

Get started

Are you an academic?

Advance research, generate impact and secure funding by partnering with industry teams around the world.

Get started

Part of a university?

Engage with industry teams from all sectors looking for a wide range of opportunities from early-stage to late-stage research, technologies, spin-outs and expertise for consultancy.

Request a demo
WHITE PAPER OUT NOWMicrobiome research trends:

Leveraging the microbiome to prevent disease and improve health